U.S. Markets closed

Research Report Identifies Myriad Genetics, Celldex Therapeutics, Charles River Laboratories International, Louisiana-Pacific, Integrated Device Technology, and Beazer Homes with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

NEW YORK, Aug. 01, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Myriad Genetics, Inc. (MYGN), Celldex Therapeutics, Inc. (CLDX), Charles River Laboratories International, Inc. (CRL), Louisiana-Pacific Corporation (LPX), Integrated Device Technology, Inc. (IDTI), and Beazer Homes USA, Inc. (BZH), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

Complimentary Access: Research Reports

Full copies of recently published reports are available to readers at the links below.

MYGN DOWNLOAD: http://Fundamental-Markets.com/register/?so=MYGN
CLDX DOWNLOAD: http://Fundamental-Markets.com/register/?so=CLDX
CRL DOWNLOAD: http://Fundamental-Markets.com/register/?so=CRL
LPX DOWNLOAD: http://Fundamental-Markets.com/register/?so=LPX
IDTI DOWNLOAD: http://Fundamental-Markets.com/register/?so=IDTI
BZH DOWNLOAD: http://Fundamental-Markets.com/register/?so=BZH

(You may have to copy and paste the link into your browser and hit the [ENTER] key)

The new research reports from Fundamental Markets, available for free download at the links above, examine Myriad Genetics, Inc. (MYGN), Celldex Therapeutics, Inc. (CLDX), Charles River Laboratories International, Inc. (CRL), Louisiana-Pacific Corporation (LPX), Integrated Device Technology, Inc. (IDTI), and Beazer Homes USA, Inc. (BZH) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.

-----------------------------------------

Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All information in this release was accessed July 30th, 2018. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.

-----------------------------------------

MYRIAD GENETICS, INC. (MYGN) REPORT OVERVIEW

Myriad Genetics' Recent Financial Performance

For the three months ended March 31st, 2018 vs March 31st, 2017, Myriad Genetics reported revenue of $193.50MM vs $196.90MM (down 1.73%) and basic earnings per share $0.16 vs $0.06 (up 166.67%). For the twelve months ended June 30th, 2017 vs June 30th, 2016, Myriad Genetics reported revenue of $771.40MM vs $753.80MM (up 2.33%) and basic earnings per share $0.32 vs $1.79 (down 82.12%). Myriad Genetics is expected to report earnings on August 14th, 2018. The report will be for the fiscal period ending June 30th, 2018. The reported EPS for the same quarter last year was $0.30. The estimated EPS forecast for the next fiscal year is $1.42 and is expected to report on August 14th, 2018.

To read the full Myriad Genetics, Inc. (MYGN) report, download it here: http://Fundamental-Markets.com/register/?so=MYGN

-----------------------------------------

CELLDEX THERAPEUTICS, INC. (CLDX) REPORT OVERVIEW

Celldex Therapeutics' Recent Financial Performance

For the three months ended March 31st, 2018 vs March 31st, 2017, Celldex Therapeutics reported revenue of $4.07MM vs $1.53MM (up 165.19%) and basic earnings per share -$0.84 vs -$0.28. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Celldex Therapeutics reported revenue of $12.74MM vs $6.79MM (up 87.78%) and basic earnings per share -$0.72 vs -$1.27. Celldex Therapeutics is expected to report earnings on August 14th, 2018. The report will be for the fiscal period ending June 30th, 2018. The reported EPS for the same quarter last year was -$0.23. The estimated EPS forecast for the next fiscal year is -$0.58 and is expected to report on March 6th, 2019.

To read the full Celldex Therapeutics, Inc. (CLDX) report, download it here: http://Fundamental-Markets.com/register/?so=CLDX

-----------------------------------------

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) REPORT OVERVIEW

Charles River Laboratories International's Recent Financial Performance

For the three months ended March 31st, 2018 vs March 31st, 2017, Charles River Laboratories International reported revenue of $493.97MM vs $445.76MM (up 10.81%) and basic earnings per share $1.10 vs $0.98 (up 12.24%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, Charles River Laboratories International reported revenue of $1,857.60MM vs $1,681.43MM (up 10.48%) and basic earnings per share $2.60 vs $3.29 (down 20.97%). Charles River Laboratories International is expected to report earnings on August 8th, 2018. The report will be for the fiscal period ending June 30th, 2018. The reported EPS for the same quarter last year was $1.29. The estimated EPS forecast for the next fiscal year is $6.53 and is expected to report on February 12th, 2019.

To read the full Charles River Laboratories International, Inc. (CRL) report, download it here: http://Fundamental-Markets.com/register/?so=CRL

-----------------------------------------

LOUISIANA-PACIFIC CORPORATION (LPX) REPORT OVERVIEW

Louisiana-Pacific's Recent Financial Performance

For the three months ended March 31st, 2018 vs March 31st, 2017, Louisiana-Pacific reported revenue of $691.30MM vs $610.90MM (up 13.16%) and basic earnings per share $0.63 vs $0.38 (up 65.79%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, Louisiana-Pacific reported revenue of $2,733.90MM vs $2,233.40MM (up 22.41%) and basic earnings per share $2.70 vs $1.04 (up 159.62%). Louisiana-Pacific is expected to report earnings on August 7th, 2018. The report will be for the fiscal period ending June 30th, 2018. The reported EPS for the same quarter last year was $0.58. The estimated EPS forecast for the next fiscal year is $2.83 and is expected to report on February 12th, 2019.

To read the full Louisiana-Pacific Corporation (LPX) report, download it here: http://Fundamental-Markets.com/register/?so=LPX

-----------------------------------------

INTEGRATED DEVICE TECHNOLOGY, INC. (IDTI) REPORT OVERVIEW

Integrated Device Technology's Recent Financial Performance

For the three months ended March 31st, 2018 vs March 31st, 2017, Integrated Device Technology reported revenue of $224.58MM vs $175.70MM (up 27.82%) and basic earnings per share $0.15 vs $0.23 (down 34.78%). For the twelve months ended March 31st, 2018 vs March 31st, 2017, Integrated Device Technology reported revenue of $842.76MM vs $728.24MM (up 15.73%) and basic earnings per share -$0.09 vs $0.83. Integrated Device Technology is expected to report earnings on October 29th, 2018. The report will be for the fiscal period ending September 30th, 2018. The reported EPS for the same quarter last year was $0.26.

To read the full Integrated Device Technology, Inc. (IDTI) report, download it here: http://Fundamental-Markets.com/register/?so=IDTI

-----------------------------------------

BEAZER HOMES USA, INC. (BZH) REPORT OVERVIEW

Beazer Homes' Recent Financial Performance

For the three months ended June 30th, 2018 vs June 30th, 2017, Beazer Homes reported revenue of $511.52MM vs $478.59MM (up 6.88%) and basic earnings per share $0.42 vs $0.22 (up 90.91%). For the twelve months ended September 30th, 2017 vs September 30th, 2016, Beazer Homes reported revenue of $1,916.28MM vs $1,822.11MM (up 5.17%) and basic earnings per share $1.00 vs $0.15 (up 566.67%). Beazer Homes is expected to report earnings on November 13th, 2018. The report will be for the fiscal period ending September 30th, 2018. The reported EPS for the same quarter last year was $0.99. The estimated EPS forecast for the next fiscal year is $2.50 and is expected to report on November 13th, 2018.

To read the full Beazer Homes USA, Inc. (BZH) report, download it here: http://Fundamental-Markets.com/register/?so=BZH

-----------------------------------------

ABOUT FUNDAMENTAL MARKETS

Fundamental Markets serves thousands of members and have provided research through some of the world's leading brokerages for over a decade–and continue to be one of the best information sources for investors and investment professionals worldwide. Fundamental Markets' roster boasts decades of financial experience and includes top financial writers, FINRA® BrokerCheck® certified professionals with current and valid CRD® number designations, as well as Chartered Financial Analyst® (CFA®) designation holders, to ensure up to date factual information for active readers on the topics they care about.

REGISTERED MEMBER STATUS

Fundamental Markets' oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Fundamental Markets' roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Fundamental Markets have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Fundamental Markets' Compliance department by Phone, at +1 667-401-0010, or by E-mail at compliance@Fundamental-Markets.com.

LEGAL NOTICES

Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Fundamental Markets, Fundamental Markets members, and/or Fundamental Markets affiliates are not responsible for any gains or losses that result from the opinions expressed. Fundamental Markets makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Fundamental Markets has not been compensated for the publication of this press release by any of the above mentioned companies. Fundamental Markets is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.

Media Contact:
Andrew Duffie, Media Department
Office: +1 667-401-0010
E-mail: media@Fundamental-Markets.com

© 2018 Fundamental Markets. All Rights Reserved. For republishing permissions, please contact a partner network manager at partnership@Fundamental-Markets.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.